Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
| ▸ | PRKCA | P17252 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | ANTXR2 | P58335 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
| ▸ | HMGCR | P04035 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22063762 | 0.97 | TSHR (0.41) | TSHRPAX8PRKCAAKT1PTK2 | |
| SCHEMBL16298992 | 0.96 | TSHR (0.47) | TSHRPAX8PRKCAAKT1PTK2 | |
| SCHEMBL20023215 | 0.96 | TSHR (0.47) | TSHRPAX8PRKCAAKT1PTK2 | |
| SCHEMBL21665520 | 0.95 | TSHR (0.44) | TSHRPAX8PRKCAAKT1PTK2 | |
| SCHEMBL18031017 | 0.94 | TSHR (0.44) | TSHRPAX8PRKCAAKT1PTK2 | |
| SCHEMBL22039261 | 0.93 | TSHR (0.44) | TSHRPAX8PRKCAAKT1PTK2 | |
| SCHEMBL25981885 | 0.92 | TSHR (0.43) | TSHRPAX8PRKCAAKT1PTK2 | |
| SCHEMBL14199422 | 0.92 | TSHR (0.48) | TSHRPAX8PRKCAAKT1PTK2 | |
| SCHEMBL23011621 | 0.90 | PTPN1 (0.43) | TSHRPAX8PRKCAAKT1PTK2 | |
| SCHEMBL14199417 | 0.90 | TSHR (0.47) | TSHRPAX8PRKCAAKT1PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128522-A1 | HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2023-04-27 | — | — | US | disclosed |
| US-20220235358-A1 | ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2022-07-28 | — | — | US | disclosed |
| US-20220127615-A1 | CORONAVIRUS IRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2022-04-28 | — | — | US | disclosed |
| US-20220127618-A1 | KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC | 2022-04-28 | — | — | US | disclosed |
| US-20210388360-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF PROTEIN C (PROC) GENES | ALNYLAM PHARMACEUTICALS, INC. | 2021-12-16 | — | — | US | disclosed |
| US-20190350962-A1 | METHODS FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES USING TRANSTHYRETIN (TTR) iRNA COMPOSITIONS | ALNYLAM PHARMACEUTICALS, INC. | 2019-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190350962-A1 | METHODS FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES USING TRANSTHYRETIN (TTR) iRNA COMPOSITIONS | TTR, SARNP, MTPN | TSHR 626/4885PAX8 1927/4885PRKCA 3579/4885 |
| US-20230128522-A1 | HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | HAVCR2, EIF2AK2, ADAR | TSHR 3817/4885PAX8 1505/4885PRKCA 1434/4885 |
| US-20220127618-A1 | KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | GCKR, KHK, HK1 | TSHR 1776/4885PAX8 1928/4885PRKCA 288/4885 |
| US-20220235358-A1 | ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | TEK, RNASE1, LDLR | TSHR 2165/4885PAX8 2273/4885PRKCA 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.